Education
About Us
Working with TipRanks
Follow Us
Globus Medical (GMED)
NYSE:GMED
GMED Stock Chart & Stats
$92.46
$2.66(3.19%)
At close: 4:00 PM EST
$92.46
$2.66(3.19%)
Day’s Range― - ―
52-Week Range$51.79 - $101.40
Previous CloseN/A
Volume442.39K
Average Volume (3M)1.68M
Market Cap
$12.45B
Enterprise Value$7.48B
Total Cash (Recent Filing)$390.52M
Total Debt (Recent Filing)$119.34M
Price to Earnings (P/E)29.9
Beta0.77
Next Earnings
Feb 19, 2026EPS Estimate
1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.18
Shares Outstanding112,175,354
10 Day Avg. Volume1,610,796
30 Day Avg. Volume1,684,810
Financial Highlights & Ratios
PEG Ratio-3.60
Price to Book (P/B)2.69
Price to Sales (P/S)4.46
P/FCF Ratio27.70
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue2.70
Enterprise Value/Gross Profit4.20
Enterprise Value/Ebitda10.42
Forecast
1Y Price Target
$105.60Price Target Upside14.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Guidance And OutlookManagement issued FY26 guidance above analyst expectations, supporting forecasts for stronger revenue growth and potential operating leverage that could lift earnings estimates.
Product Portfolio ExpansionLaunches and regulatory clearances of new platforms such as ExcelsiusXR and additional instrument approvals should expand the addressable market and drive future capital equipment demand.
US Spine MomentumSustained strength in the US Spine business with accelerating sales and market-share gains suggests continued musculoskeletal revenue expansion and positive read-through for peers.
Bears Say
Capital Sales Cycle RiskEnabling Technologies faces elongated capital sale cycles that can delay recognition of robotic-system revenue and introduce quarter-to-quarter volatility in results.
Shift To LeasingA meaningful shift from outright purchases to leasing of robotic systems reduces upfront revenue and could depress near-term top-line growth despite a healthy project pipeline.
Valuation And Margin ConstraintsChallenging comparable-period dynamics and limited scope for margin expansion imply the stock may trade in line with medical-technology peers, constraining upside potential.
Globus Medical News
GMED FAQ
What was Globus Medical’s price range in the past 12 months?
Globus Medical lowest stock price was $51.79 and its highest was $101.40 in the past 12 months.
What is Globus Medical’s market cap?
Globus Medical’s market cap is $12.45B.
When is Globus Medical’s upcoming earnings report date?
Globus Medical’s upcoming earnings report date is Feb 19, 2026 which is in 34 days.
How were Globus Medical’s earnings last quarter?
Globus Medical released its earnings results on Nov 06, 2025. The company reported $1.18 earnings per share for the quarter, beating the consensus estimate of $0.781 by $0.399.
Is Globus Medical overvalued?
According to Wall Street analysts Globus Medical’s price is currently Undervalued.
Does Globus Medical pay dividends?
Globus Medical does not currently pay dividends.
What is Globus Medical’s EPS estimate?
Globus Medical’s EPS estimate is 1.11.
How many shares outstanding does Globus Medical have?
Globus Medical has 112,175,354 shares outstanding.
What happened to Globus Medical’s price movement after its last earnings report?
Globus Medical reported an EPS of $1.18 in its last earnings report, beating expectations of $0.781. Following the earnings report the stock price went up 35.942%.
Which hedge fund is a major shareholder of Globus Medical?
Currently, no hedge funds are holding shares in GMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Globus Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$105.60 (14.21% Upside)
$105.60 (14.21% Upside)
Hedge Fund Trend
Increased
By 352.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.2%
Last 30 Days ▲ 35.1%
Last 30 Days ▲ 35.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.82%
12-Months-Change
Fundamentals
Return on Equity
10.01%
Trailing 12-Months
Asset Growth
0.19%
Trailing 12-Months
Company Description
Globus Medical
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
GMED Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Globus Medical was predominantly positive, with significant revenue and earnings growth, successful integration of Nevro, and strong performances in the U.S. Spine and Trauma segments. Despite these successes, there were challenges in the Enabling Technologies segment, including a decline in revenue and slower capital sales. The company's ability to adapt to market conditions and its strong cash flow generation underscore a solid financial position.View all GMED earnings summariesGMED Net sales Breakdown
92.34% Musculoskeletal Solutions
7.66% Enabling Technologies
GMED Stock 12 Month Forecast
Average Price Target
$105.60
▲(14.21% Upside)
Technical Analysis
Boston Scientific
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Stryker
―
Zimmer Biomet Holdings
―
Ownership Overview
0.72% Insiders
33.59% Mutual Funds
0.96% Other Institutional Investors
42.71% Public Companies and
Individual Investors